268 related articles for article (PubMed ID: 9829737)
1. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study.
Taber SW; Fingar VH; Coots CT; Wieman TJ
Clin Cancer Res; 1998 Nov; 4(11):2741-6. PubMed ID: 9829737
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces.
Chan AL; Juarez M; Allen R; Volz W; Albertson T
Photodermatol Photoimmunol Photomed; 2005 Apr; 21(2):72-8. PubMed ID: 15752124
[TBL] [Abstract][Full Text] [Related]
3. Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model.
Wong Kee Song LM; Wang KK; Zinsmeister AR
Cancer; 1998 Jan; 82(2):421-7. PubMed ID: 9445202
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy with mono-L-aspartyl chlorin e6 can cause necrosis of squamous cell carcinoma of tongue: experimental study on an animal model of nude mouse.
Kobayashi W; Liu Q; Nakagawa H; Sakaki H; Teh B; Matsumiya T; Yoshida H; Imaizumi T; Satoh K; Kimura H
Oral Oncol; 2006 Jan; 42(1):46-50. PubMed ID: 16266818
[TBL] [Abstract][Full Text] [Related]
5. Tissue distribution and photosensitizing properties of mono-L-aspartyl chlorin e6 in a mouse tumor model.
Gomer CJ; Ferrario A
Cancer Res; 1990 Jul; 50(13):3985-90. PubMed ID: 2354446
[TBL] [Abstract][Full Text] [Related]
6. Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessel constriction, vessel leakage, and tumor response.
McMahon KS; Wieman TJ; Moore PH; Fingar VH
Cancer Res; 1994 Oct; 54(20):5374-9. PubMed ID: 7923168
[TBL] [Abstract][Full Text] [Related]
7. Metabolic properties and photosensitizing responsiveness of mono-L-aspartyl chlorin e6 in a mouse tumor model.
Ferrario A; Kessel D; Gomer CJ
Cancer Res; 1992 May; 52(10):2890-3. PubMed ID: 1581904
[TBL] [Abstract][Full Text] [Related]
8. Photodynamic therapy of intestinal tumors with mono-L-aspartyl chlorin e6 (NPe6): a basic study.
Kikuchi T; Asakura T; Aihara H; Shiraki M; Takagi S; Kinouchi Y; Aizawa K; Shimosegawa T
Anticancer Res; 2003; 23(6C):4897-900. PubMed ID: 14981942
[TBL] [Abstract][Full Text] [Related]
9. Effects of photodynamic therapy using a fractionated dosing of mono-L-aspartyl chlorin e6 in a murine tumor.
Webber J; Leeson B; Fromm D; Kessel D
J Photochem Photobiol B; 2005 Feb; 78(2):135-40. PubMed ID: 15664500
[TBL] [Abstract][Full Text] [Related]
10. Endovascular photodynamic therapy using mono-L-aspartyl-chlorin e6 to inhibit Intimal hyperplasia in balloon-injured rabbit arteries.
Nagae T; Aizawa K; Uchimura N; Tani D; Abe M; Fujishima K; Wilson SE; Ishimaru S
Lasers Surg Med; 2001; 28(4):381-8. PubMed ID: 11344521
[TBL] [Abstract][Full Text] [Related]
11. Outcome of photodynamic therapy using NPe6 for bronchogenic carcinomas in central airways >1.0 cm in diameter.
Usuda J; Ichinose S; Ishizumi T; Hayashi H; Ohtani K; Maehara S; Ono S; Honda H; Kajiwara N; Uchida O; Tsutsui H; Ohira T; Kato H; Ikeda N
Clin Cancer Res; 2010 Apr; 16(7):2198-204. PubMed ID: 20332318
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung.
Kato H; Furukawa K; Sato M; Okunaka T; Kusunoki Y; Kawahara M; Fukuoka M; Miyazawa T; Yana T; Matsui K; Shiraishi T; Horinouchi H
Lung Cancer; 2003 Oct; 42(1):103-11. PubMed ID: 14512194
[TBL] [Abstract][Full Text] [Related]
13. [A basic study of photodynamic therapy of experimental hepatoma with ME 2906].
Nakamura J; Kajiwara H; Nakamura M; Watanabe M; Naganuma K; Tanaka H; Usui S; Sumiyama Y; Saito K; Aizawa K
Gan To Kagaku Ryoho; 1998 Jul; 25(9):1454-6. PubMed ID: 9703852
[TBL] [Abstract][Full Text] [Related]
14. The effects of serum on cellular uptake and phototoxicity of mono-L-aspartyl chlorin e6 (NPe6) in vitro.
Sheyhedin I; Aizawa K; Araake M; Kumasaka H; Okunaka T; Kato H
Photochem Photobiol; 1998 Jul; 68(1):110-4. PubMed ID: 9679456
[TBL] [Abstract][Full Text] [Related]
15. Treatment of squamous cell carcinoma of the lip using Foscan-mediated photodynamic therapy.
Kübler AC; de Carpentier J; Hopper C; Leonard AG; Putnam G
Int J Oral Maxillofac Surg; 2001 Dec; 30(6):504-9. PubMed ID: 11829232
[TBL] [Abstract][Full Text] [Related]
16. Angiographic and histologic effects of fundus photodynamic therapy with a hydrophilic sensitizer (mono-L-aspartyl chlorin e6).
Mori K; Yoneya S; Ohta M; Sano A; Anzai K; Peyman GA; Moshfeghi DM
Ophthalmology; 1999 Jul; 106(7):1384-91. PubMed ID: 10406627
[TBL] [Abstract][Full Text] [Related]
17. In vivo studies on the utilization of mono-L-aspartyl chlorin (NPe6) for photodynamic therapy.
Nelson JS; Roberts WG; Berns MW
Cancer Res; 1987 Sep; 47(17):4681-5. PubMed ID: 2957047
[TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy for lung cancers based on novel photodynamic diagnosis using talaporfin sodium (NPe6) and autofluorescence bronchoscopy.
Usuda J; Tsutsui H; Honda H; Ichinose S; Ishizumi T; Hirata T; Inoue T; Ohtani K; Maehara S; Imai K; Tsunoda Y; Kubota M; Ikeda N; Furukawa K; Okunaka T; Kato H
Lung Cancer; 2007 Dec; 58(3):317-23. PubMed ID: 17698240
[TBL] [Abstract][Full Text] [Related]
19. Expression of vascular endothelial growth factor by photodynamic therapy with mono-L-aspartyl chlorin e6 (NPe6) in oral squamous cell carcinoma.
Nakagawa H; Matsumiya T; Sakaki H; Imaizumi T; Kubota K; Kusumi A; Kobayashi W; Kimura H
Oral Oncol; 2007 Jul; 43(6):544-50. PubMed ID: 17257889
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
